PLoS ONE (Jan 2012)

Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B.

  • Mathias Gehrmann,
  • Stefan Stangl,
  • Andreas Kirschner,
  • Gemma A Foulds,
  • Wolfgang Sievert,
  • Brigitte T Doss,
  • Axel Walch,
  • Alan G Pockley,
  • Gabriele Multhoff

DOI
https://doi.org/10.1371/journal.pone.0041341
Journal volume & issue
Vol. 7, no. 7
p. e41341

Abstract

Read online

BackgroundWe have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner.Methodology/principal findingsOptical imaging of uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral concentrations of grB elicited no clinicopathological changes.Conclusions/significanceThese findings support the future clinical evaluation of human grB as a potential adjuvant therapeutic agent, especially for treating immunosuppressed patients that bear membrane Hsp70-positive tumors.